封面
市場調查報告書
商品編碼
1668143

支氣管炎治療市場 - 全球產業規模、佔有率、趨勢、機會和預測,按藥物類別、類型、最終用戶、地區和競爭細分,2020-2030 年預測

Bronchitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Class of Drugs, By Type, By End User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球支氣管炎治療市值為 83.6 億美元,預計到 2030 年將達到 95.6 億美元,預測期內複合年成長率為 5.21%。支氣管炎是一種呼吸系統疾病,其特徵是支氣管發炎,通常由病毒或細菌感染引起。全球支氣管炎治療市場涵蓋旨在控制和緩解支氣管炎症狀的藥品、療法和醫療設備。醫學研究的不斷進步導致了創新支氣管炎治療方案的發展。根據美國國家生物中心 2022 年 2 月的一篇題為「急性支氣管炎」的文章,估計每年有 5% 的普通人群會經歷一次急性支氣管炎,導致每年超過 1000 萬人次就診。因此,支氣管炎盛行率的不斷上升推動了治療需求,進而推動了市場的成長。

市場概況
預測期 2026-2030
2024 年市場規模 83.6 億美元
2030 年市場規模 95.6 億美元
2025-2030 年複合年成長率 5.21%
成長最快的領域 支氣管擴張劑
最大的市場 北美洲

製藥公司正在投資研發新藥物和新療法,為患者提供更好的治療效果。這些醫學突破透過提供更有效、更有針對性的治療方法正在擴大市場。

旨在推廣流感等呼吸道感染疫苗接種的公共衛生措施正在降低支氣管炎的風險。增強對預防措施的認知,例如適當的手部衛生和避免接觸刺激物,有助於減少支氣管炎病例。隨著這些措施的實施,重點轉向現有病例的管理和治療,進一步促進支氣管炎治療市場的發展。城市化和更忙碌、緊張的生活方式導致了吸煙習慣的增加。隨著人們搬到城市並面臨現代生活的壓力,有些人選擇吸煙作為一種應對機制。都市生活方式使得不良習慣更普遍,導致支氣管炎發生率更高,因此治療需求也更大。

主要市場促進因素

支氣管炎盛行率高

主要市場挑戰

抗生素抗藥性

主要市場趨勢

改變生活方式和吸煙習慣

區域洞察

目錄

第 1 章:產品概述

第 2 章:研究方法

第 3 章:執行摘要

第 4 章:顧客之聲

第5章:全球支氣管炎治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類別(抗生素、消炎藥、支氣管擴張藥、其他)
    • 依類型(急性支氣管炎、慢性支氣管炎)
    • 按最終用戶(醫院藥房、零售藥房、其他)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖

第 6 章:北美支氣管炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 加拿大
    • 墨西哥

第 7 章:歐洲支氣管炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章:亞太地區支氣管炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章:南美洲支氣管炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章:中東和非洲支氣管炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 合併與收購(如有)
  • 產品發布(如果有)
  • 最新動態

第 13 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章:競爭格局

  • AstraZeneca PLC
  • Novartis AG
  • GSK PLC
  • Dr. Reddy's Laboratories Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc
  • Melinta Therapeutics Inc
  • Lupin Ltd
  • Cadila Pharmaceuticals Ltd

第 15 章:策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 18856

Global Bronchitis Treatment Market was valued at USD 8.36 Billion in 2024 and is expected to reach USD 9.56 Billion by 2030 with a CAGR of 5.21% during the forecast period. Bronchitis is a respiratory condition characterized by inflammation of the bronchial tubes, often resulting from viral or bacterial infections. The global bronchitis treatment market encompasses pharmaceuticals, therapies, and medical devices aimed at managing and alleviating the symptoms of bronchitis. Continuous advancements in medical research have led to the development of innovative bronchitis treatment options. According to a February 2022 article by the National Center for Bio, titled "Acute Bronchitis," it is estimated that 5% of the general population experiences an episode of acute bronchitis annually, resulting in over 10 million office visits each year. Consequently, the increasing prevalence of bronchitis is driving the demand for treatment, which in turn is fueling market growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 8.36 Billion
Market Size 2030USD 9.56 Billion
CAGR 2025-20305.21%
Fastest Growing SegmentBronchodilator
Largest MarketNorth America

Pharmaceutical companies are investing in creating new medications and therapies that offer better outcomes for patients. These medical breakthroughs are expanding the market by providing more effective and targeted treatment approaches.

Public health initiatives aimed at promoting vaccination against respiratory infections like influenza are reducing the risk of bronchitis. Increased awareness about preventive measures, such as proper hand hygiene and avoiding exposure to irritants, is contributing to a reduction in bronchitis cases. As these measures gain traction, the focus shifts to the management and treatment of existing cases, further boosting the bronchitis treatment market. Urbanization and the adoption of more hectic and stressful lifestyles contribute to an increase in smoking habits. As people move to urban areas and face the pressures of modern life, some turn to smoking as a coping mechanism. The urban lifestyle fosters environments where unhealthy habits are more prevalent, leading to a higher incidence of bronchitis and, consequently, greater demand for treatment.

Key Market Drivers

High Prevalence of Bronchitis

Bronchitis, a common respiratory condition characterized by the inflammation of the bronchial tubes, poses a significant health concern worldwide. The global bronchitis treatment market is experiencing substantial growth, and one of the primary driving forces behind this expansion is the high prevalence of bronchitis.

The high prevalence of bronchitis means that a substantial number of individuals are affected by this condition. Bronchitis can be acute or chronic and may result from various factors such as respiratory infections, smoking, and exposure to environmental pollutants. With millions of people being diagnosed with bronchitis each year, there is a consistent and growing demand for effective treatment options. The world's population is aging, with a significant proportion of individuals aged 65 and older. This demographic group is more susceptible to respiratory conditions, including chronic bronchitis. As the elderly population continues to expand, the market for bronchitis treatment is expected to grow in tandem.

Rapid urbanization has led to increased exposure to air pollution, a known risk factor for bronchitis. In densely populated urban areas with high levels of air pollution, the prevalence of bronchitis is notably elevated. As urbanization persists globally, so does the demand for bronchitis treatment, driven by the adverse effects of polluted air on respiratory health. Lifestyle factors play a significant role in the development of bronchitis. Smoking, both active and passive, remains a prominent risk factor for bronchitis. However, public health campaigns and increasing awareness about the dangers of smoking are driving more individuals to seek treatment for bronchitis symptoms. This heightened awareness is boosting the market as more patients are diagnosed and treated. In February 2022, the United States Food and Drug Administration (USFDA) granted approval to Lupin Limited's generic version of Brovana (arformoterol tartrate) for the treatment of bronchoconstriction in individuals with chronic obstructive pulmonary disease (COPD). The active ingredient in Brovana is a bronchodilator, which works by relaxing and widening the airways, thereby reducing bronchoconstriction.

Access to healthcare services is expanding in many parts of the world, enabling individuals to seek diagnosis and treatment for bronchitis more readily. The increasing availability of healthcare facilities and professionals is instrumental in driving market growth, as individuals are more likely to receive proper care and treatment.

Key Market Challenges

Antibiotic Resistance

Antibiotic resistance is an escalating concern in the treatment of bronchitis, particularly bacterial bronchitis. The widespread use of antibiotics, often as a first-line treatment, has led to the emergence of resistant bacterial strains, making standard therapies less effective. Overprescription, patient non-compliance with prescribed courses, and the use of broad-spectrum antibiotics when narrow-spectrum options may suffice contribute to this growing issue. As resistant bacteria become more prevalent, healthcare providers face increasing difficulties in managing infections, leading to prolonged illness durations and higher risks of complications.

Antibiotic resistance limits the availability of effective medications, forcing the medical community to seek alternative treatments, such as combination therapies or newer, more expensive antibiotics. These alternatives may not always be accessible or affordable, particularly in low-resource settings. In some cases, treatment failure due to resistance can result in hospitalizations and increased healthcare costs. Resistant strains can spread within communities and healthcare facilities, exacerbating the problem.

Efforts to combat antibiotic resistance include promoting antimicrobial stewardship programs, educating healthcare professionals and patients on responsible antibiotic use, and encouraging the development of novel therapeutics. Greater emphasis on preventive measures, such as vaccinations and public awareness campaigns, can also help reduce the reliance on antibiotics. By implementing stricter guidelines on antibiotic prescription and usage, healthcare systems can work toward mitigating the long-term consequences of resistance, ensuring that bronchitis and other bacterial infections remain treatable in the future.

Key Market Trends

Changing Lifestyles and Smoking Habits

Bronchitis, a common respiratory condition characterized by inflammation of the bronchial tubes, is often linked to lifestyle choices and smoking habits. As individuals increasingly adopt unhealthy lifestyles and continue to smoke, the global bronchitis treatment market is experiencing significant growth. Smoking remains one of the most significant risk factors for developing bronchitis. Tobacco smoke contains harmful chemicals that irritate the airways and increase susceptibility to respiratory infections. Despite ongoing efforts to curb smoking, a substantial portion of the global population continues to smoke or be exposed to secondhand smoke.

Changing lifestyles are often accompanied by increased awareness of the health risks associated with smoking. Public health campaigns and educational initiatives have raised awareness about the dangers of tobacco use. Smokers are increasingly seeking help to quit, and this heightened awareness drives individuals to seek medical assistance and treatment for bronchitis symptoms. Even non-smokers can develop bronchitis due to exposure to secondhand smoke. In households or public spaces where smoking is prevalent, individuals who do not smoke themselves may still face the health consequences of inhaling tobacco smoke. The rising awareness of these risks has led to greater demand for bronchitis treatment.

Chronic bronchitis, often linked to long-term smoking, is a persistent form of the condition that requires ongoing treatment. Individuals with chronic bronchitis experience recurrent symptoms and require regular medical attention. As the number of individuals with chronic bronchitis grows due to smoking habits, the market for bronchitis treatment expands accordingly. The demand for bronchitis treatment has spurred pharmaceutical companies to invest in research and development. New medications and therapies are continually being developed to provide more effective and targeted treatment options for bronchitis patients. As these innovations become available, they enhance the overall market for bronchitis treatment.

Regional Insights

North America hold a dominant position, and this trend is expected to persist throughout the forecasted period. Specifically, within North America, the United States has established a significant presence in the bronchitis treatment market. This prominence can be attributed to various factors, including the rising incidence of bronchitis cases, a growing prevalence of smoking among the younger population, and a surge in strategic initiatives undertaken by key market players. United States received diagnoses related to chronic obstructive pulmonary disease (COPD), emphysema, or chronic emphysema. Given the association between COPD and bronchitis, there is a substantial demand for bronchitis treatment in the country, contributing significantly to market expansion. several market participants are actively pursuing strategic endeavors, further bolstering market growth. As an illustration, in June 2021, Lupin introduced Arformoterol, a generic inhalation product designed for the treatment of chronic bronchitis, into the United States market. These developments are expected to catalyze the creation of more such products and their subsequent approvals for bronchitis treatment in the nation, thus fostering continued market growth in the foreseeable future.

Key Market Players

  • AstraZeneca PLC
  • Novartis AG
  • GSK PLC
  • Dr. Reddy's Laboratories Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc
  • Melinta Therapeutics Inc
  • Lupin Ltd
  • Cadila Pharmaceuticals Ltd

Report Scope:

In this report, the Global Bronchitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bronchitis Treatment Market, By Class of Drugs:

  • Antibiotics
  • Anti-inflammatory Drugs
  • Bronchodilator
  • Others

Bronchitis Treatment Market, By Type:

  • Acute Bronchitis
  • Chronic Bronchitis

Bronchitis Treatment Market, By End User:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Bronchitis Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bronchitis Treatment Market.

Available Customizations:

Global Bronchitis Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bronchitis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Class of Drugs (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Others)
    • 5.2.2. By Type (Acute Bronchitis, Chronic Bronchitis)
    • 5.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Bronchitis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Class of Drugs
    • 6.2.2. By Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bronchitis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Class of Drugs
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Bronchitis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Class of Drugs
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Bronchitis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Class of Drugs
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End User

7. Europe Bronchitis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Class of Drugs
    • 7.2.2. By Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bronchitis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Class of Drugs
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Bronchitis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Class of Drugs
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Bronchitis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Class of Drugs
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User
    • 7.3.4. France Bronchitis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Class of Drugs
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Bronchitis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Class of Drugs
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End User

8. Asia-Pacific Bronchitis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Class of Drugs
    • 8.2.2. By Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bronchitis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Class of Drugs
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Bronchitis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Class of Drugs
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Bronchitis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Class of Drugs
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Bronchitis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Class of Drugs
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Bronchitis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Class of Drugs
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. South America Bronchitis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Class of Drugs
    • 9.2.2. By Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bronchitis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Class of Drugs
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Bronchitis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Class of Drugs
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Bronchitis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Class of Drugs
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User

10. Middle East and Africa Bronchitis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Class of Drugs
    • 10.2.2. By Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bronchitis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Class of Drugs
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Bronchitis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Class of Drugs
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Bronchitis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Class of Drugs
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. AstraZeneca PLC
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Novartis AG
  • 14.3. GSK PLC
  • 14.4. Dr. Reddy's Laboratories Ltd
  • 14.5. Sanofi SA
  • 14.6. Boehringer Ingelheim International GmbH
  • 14.7. Pfizer Inc
  • 14.8. Melinta Therapeutics Inc
  • 14.9. Lupin Ltd
  • 14.10. Cadila Pharmaceuticals Ltd

15. Strategic Recommendations

16. About Us & Disclaimer